These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22107359)

  • 1. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.
    Nanzigu S; Eriksen J; Makumbi F; Lanke S; Mahindi M; Kiguba R; Beck O; Ma Q; Morse GD; Gustafsson LL; Waako P
    HIV Med; 2012 Apr; 13(4):193-201. PubMed ID: 22107359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
    Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
    Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
    Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.
    von Hentig N; Koenigs C; Elanjikal S; Linde R; Dunsch D; Kreuz W; Funk MB
    Eur J Med Res; 2006 Sep; 11(9):377-80. PubMed ID: 17101460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
    Kityo C; Walker AS; Dickinson L; Lutwama F; Kayiwa J; Ssali F; Nalumenya R; Tumukunde D; Munderi P; Reid A; Gilks CF; Gibb DM; Khoo S;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2965-73. PubMed ID: 20421406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
    Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
    Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.
    Ngaimisi E; Mugusi S; Minzi OM; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Burhenne J; Aklillu E
    Clin Pharmacol Ther; 2010 Nov; 88(5):676-84. PubMed ID: 20881953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
    Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
    J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
    Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evidence-based therapeutic drug monitoring for efavirenz].
    Solas C; Gagnieu MC;
    Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
    Almond LM; Hoggard PG; Edirisinghe D; Khoo SH; Back DJ
    J Antimicrob Chemother; 2005 Oct; 56(4):738-44. PubMed ID: 16141277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz pharmacokinetics during pregnancy and infant washout.
    Kreitchmann R; Schalkwijk S; Best B; Wang J; Colbers A; Stek A; Shapiro D; Cressey T; Mirochnick M; Burger D
    Antivir Ther; 2019; 24(2):95-103. PubMed ID: 30530925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.